Connect with us

Hi, what are you looking for?


Russian drugmaker seeks vaccine emergency use

Russia’s Gamaleya Research Institute of Epidemiology has applied for emergency use authorization for its coronavirus vaccine in the Philippines, according to the local Food and Drug Administration (FDA).

The regulator, which got the application on Jan. 7, had ordered the drugmaker to submit missing documents, FDA Director-General Eric Domingo said on Friday.

Gamaleya withdrew its application for clinical trials of its vaccine on Jan. 6, the Department of Science and Technology (DoST) said.

“Their reason was simple — they would apply for emergency use authorization so they don’t need the clinical trials here,” Science and Technology Undersecretary Rowena Guevarra told an online news briefing.

US drugmaker Pfizer, Inc. and Britain’s AstraZeneca Plc have also filed for emergency use with the FDA.

The three already have existing emergency use approvals in other countries.

Meanwhile, the DoST said China National Pharmaceutical Group Co., Ltd. (Sinopharm) had yet to decide whether to pursue clinical trials for its coronavirus vaccine in the Philippines.

“Sinopharm has yet to decide if it will conduct a clinical trial here or just apply for an emergency use authorization,” DoST Assistant Secretary Leah J. Buenda told a televised public briefing in mixed English and Filipino.

Ms. Buendia said the agency had signed a confidentiality disclosure agreement with Sinopharm even if it had not yet received any data from the Chinese drugmaker. — Vann Marlo M. Villegas and Kyle Aristophere T. Atienza

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!



REPORTS of significant attacks against two Russian air bases are a new and dangerous twist in the Ukraine war. One of the explosions was...


The COVID-19 pandemic dealt a blow to the Philippine economy and exposed many gaps and weaknesses in our system that had been present for...


In 2016, several art scholars and museums embarked on a project to digitally produce 17th century artist Rembrandt’s next work, by using a computer...


Southeast Asia is adjusting to a new normal with the welcome return of travel and in-person gatherings, be it at work, with family and...


SINGAPORE — Jollibee Foods Corp, the biggest fast-food operator in the Philippines, is in advanced discussions to sell a minority stake in its Vietnamese...


INDONESIAN lawmakers have passed a contentious criminal code that outlaws extramarital sex and raises penalties on abortions as part of legislation that sparked violent...

You May Also Like


The minute that any question pops into your head, you can simply ask Google. No longer do we have to pour over books and...


Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...


Browsing history makes referring to sites and pages you’ve visited in the past seamless. It’ll help you recall what page you checked out on...


Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.